195
Views
4
CrossRef citations to date
0
Altmetric
Review

Recent advances in nanoformulation development of Ritonavir, a key protease inhibitor used in the treatment of HIV-AIDS

, , , &
Pages 1133-1148 | Received 06 Nov 2021, Accepted 02 Sep 2022, Published online: 08 Sep 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Alptug Karakucuk, Hande Canpinar & Nevin Celebi. (2022) Ritonavir nanosuspensions prepared by microfluidization with enhanced solubility and desirable immunological properties. Pharmaceutical Development and Technology 27:10, pages 1027-1037.
Read now

Articles from other publishers (3)

Yasunari Matsuzaka & Ryu Yashiro. (2023) Extracellular Vesicle-Based SARS-CoV-2 Vaccine. Vaccines 11:3, pages 539.
Crossref
Murtaza Haider Syed, Mior Ahmad Khushairi Mohd Zahari, Md Maksudur Rahman Khan, Mohammad Dalour Hossen Beg & Norhayati Abdullah. (2023) An overview on recent biomedical applications of biopolymers: Their role in drug delivery systems and comparison of major systems. Journal of Drug Delivery Science and Technology 80, pages 104121.
Crossref
Mahmoud Kandeel, Mohamed A. Morsy, Hany M. Abd El-Lateef, Mohamed Marzok, Hossam S. El-Beltagi, Khalid M. Al Khodair, Ibrahim Albokhadaim & Katharigatta N. Venugopala. (2023) The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. Processes 11:2, pages 398.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.